Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

PHARMATHEN RESEARCH AND DEVELOPMENT

Summary sheet

Release date
8 November 2024
Status
Reference
Under appraisal | 24/09/2024
20240259
Project name
Promoter - financial intermediary
PHARMATHEN RESEARCH AND DEVELOPMENT
PHARMATHEN SA - INDUSTRIAL AND COMMERCIAL COMPANY OF PHARMACEUTICALS AND COSMETICS
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 100 million
EUR 229 million
Location
Sector(s)
Description
Objectives

The project will finance the promoter's Research and Development (R&D) investments in the period 2025-2028.

The aim is to support Pharmathen's R&D expenditures.

Environmental aspects
Procurement

The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories Thus an Environmental Impact Assessment (EIA) is not foreseen. The RDI activities do not fall under the Annexes of the EIA Directive 2011/92/EU as amended by Directive 2014/52/EU. The full environmental details will however be investigated by the Bank's services during the due diligence stage.

The Promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the Promoter is subject to the EU public procurement legislation then the Bank would duly inform the Commission Services and would require the Promoter to apply those rules.

Milestone
Under appraisal
Link to source
Summary sheet
PHARMATHEN RESEARCH AND DEVELOPMENT

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications